Company profile
Caris Life Sciences, Inc.
NASDAQ: CAI · Healthcare · Biotechnology
#174 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
61CFH 76DQ 37GM —SS 62
v0.1 · 55/100 weight · provisional
↑ Piotroski F, market scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$989.6M
Rev growth YoY (TTM)
+85.4%
Net income (FY)
-$68.1M
Employees
1,846
as of 2026-08-07
Market cap
$5.7B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$812.0M$812.0M2025
Net income-$68.1M-$68.1M2025
Operating income$45.1M$45.1M2025
Total assets$1.1B$1.1B2025
Liabilities$548.4M$548.4M2025
Equity$577.3M$577.3M2025
Revenue trend
FY2025 – FY2025 · USD
FY25
FY25
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Caris Life Sciences, Inc.’s revenue?
Caris Life Sciences, Inc. booked $812.0M in FY2025 revenue, growing 97% year over year — faster than most Healthcare companies we track, at a -8.4% net margin.
Peers · Healthcare
Myriad Genetics, Inc.67BOrthofix Medical Inc.75B+Tilray Brands, Inc.——GoodRx Holdings, Inc.69BU.S. Physical Therapy, Inc.80B+Collegium Pharmaceutical, Inc.73BNeighbors
Dallas →Key facts
CEODavid Dean Halbert
SectorHealthcare
IndustryBiotechnology
HeadquartersIrving, TX
ExchangeNASDAQ: CAI
Employees1,846
IPO date2025-06-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.